These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36111020)

  • 41. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
    Sperr WR; Herndlhofer S; Gleixner K; Girschikofsky M; Weltermann A; Machherndl-Spandl S; Sliwa T; Poehnl R; Buxhofer-Ausch V; Strecker K; Hoermann G; Knoebl P; Jaeger U; Geissler K; Kundi M; Valent P
    Am J Hematol; 2017 Oct; 92(10):E567-E574. PubMed ID: 28699225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.
    Cornelissen JJ; Breems D; van Putten WL; Gratwohl AA; Passweg JR; Pabst T; Maertens J; Beverloo HB; van Marwijk Kooy M; Wijermans PW; Biemond BJ; Vellenga E; Verdonck LF; Ossenkoppele GJ; Löwenberg B
    J Clin Oncol; 2012 Jun; 30(17):2140-6. PubMed ID: 22564995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia.
    Shpilberg O; Haddad N; Sofer O; Raanani P; Berkowicz M; Chetrit A; Carter A; Ramot B; Tatarski I; Ben-Bassat I
    Leuk Res; 1995 Dec; 19(12):893-7. PubMed ID: 8632657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
    Karanes C; Kopecky KJ; Head DR; Grever MR; Hynes HE; Kraut EH; Vial RH; Lichtin A; Nand S; Samlowski WE; Appelbaum FR
    Leuk Res; 1999 Sep; 23(9):787-94. PubMed ID: 10475617
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prognostic Factors and Predictive Value of MRD before Consolidation Therapy in Middle-risk Newly Diagnosed Young and Middle-aged Patients with AML].
    Niu ZY; Dang HB; Yue L; Tian QS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):462-468. PubMed ID: 33812416
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia.
    Marrero RJ; Wu H; Cao X; Parcha PK; Elsayed AH; Inaba H; Kuo DJ; Degar BA; Heym K; Taub JW; Lacayo N; Pui CH; Ribeiro RC; Rubnitz JE; Pounds SB; Lamba JK
    Clin Cancer Res; 2024 Oct; 30(19):4388-4396. PubMed ID: 39078289
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
    Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Long term outcome of acute myeloid leukemia with t(8;21)].
    Li W; Mi YC; Wang Y; Fu MW; Lin D; Wang HJ; Liu XP; Bian SG; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2009 Mar; 30(3):186-91. PubMed ID: 19642369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
    Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R; Cobcroft R; Herrmann R; Van Der Weyden M; Lowenthal RM; Page F; Garson OM; Juneja S
    Blood; 1996 Mar; 87(5):1710-7. PubMed ID: 8634416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic Significance of Monosomal Karyotype in Adult Patients With Acute Myeloid Leukemia Treated With Risk-Adapted Protocols.
    Lu QS; Xu N; Zhou X; Huang JX; Li L; Li YL; Lu ZY; Cao R; Liao LB; Liu XL
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):790-6. PubMed ID: 26482108
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal Post-Remission Consolidation Therapy in Patients with AML.
    Jimenez-Chillon C; Dillon R; Russell N
    Acta Haematol; 2024; 147(2):147-158. PubMed ID: 38008085
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study.
    Wang L; Zhao N; Zhou L; Tong J; Xue L; Zhang L; Han Y; Wang X; Geng L; Tang B; Liu H; Zhu W; Cai X; Liu X; Zhu X; Sun Z; Zheng C
    Clin Interv Aging; 2022; 17():55-64. PubMed ID: 35082491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.
    Schaich M; Schlenk RF; Al-Ali HK; Döhner H; Ganser A; Heil G; Illmer T; Krahl R; Krauter J; Sauerland C; Büchner T; Ehninger G
    Haematologica; 2007 Jun; 92(6):763-70. PubMed ID: 17550848
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study.
    Grosicki S; Holowiecki J; Kuliczkowski K; Skotnicki A; Hellmann A; Kyrcz-Krzemien S; Dmoszynska A; Sułek K; Kloczko J; Jedrzejczak WW; Warzocha K; Zdziarska B; Wierzbowska A; Pluta A; Komarnicki M; Giebel S
    Am J Hematol; 2015 Oct; 90(10):904-9. PubMed ID: 26149802
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunological characterization and antibacterial function of persisting granulocytes in leukemic patients receiving pulse cytosine arabinoside-consolidation chemotherapy on days 1, 3, and 5.
    Krauth MT; Florian S; Böhm A; Sonneck K; Agis H; Samorapoompichit P; Hauswirth AW; Sperr WR; Valent P
    J Immunol; 2006 Feb; 176(3):1759-68. PubMed ID: 16424206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
    Neubauer A; Maharry K; Mrózek K; Thiede C; Marcucci G; Paschka P; Mayer RJ; Larson RA; Liu ET; Bloomfield CD
    J Clin Oncol; 2008 Oct; 26(28):4603-9. PubMed ID: 18559876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.
    Pfirrmann M; Ehninger G; Thiede C; Bornhäuser M; Kramer M; Röllig C; Hasford J; Schaich M;
    Lancet Oncol; 2012 Feb; 13(2):207-14. PubMed ID: 22197676
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
    Koreth J; Schlenk R; Kopecky KJ; Honda S; Sierra J; Djulbegovic BJ; Wadleigh M; DeAngelo DJ; Stone RM; Sakamaki H; Appelbaum FR; Döhner H; Antin JH; Soiffer RJ; Cutler C
    JAMA; 2009 Jun; 301(22):2349-61. PubMed ID: 19509382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.